MCKESSON CORP

MCKESSON CORP (MCK) — Investment Memo

🐂 The Bull Case (Warren's voice)

We aren't buying a pharmacy; we are buying the plumbing of the American healthcare system.

• The Indispensable Pipe: McKesson doesn't need a "brand" because it is the infrastructure. When a hospital needs a life-saving drug in two hours, they don't shop for price; they rely on the network. The moat is built of concrete, warehouses, and decades of regulatory licensure that no startup can replicate in a decade.
• Cash Flow over Accounting: The market obsessively watches the Net Income line, but we watch the cash. A business that can generate $5.5B in FCF while reporting a fraction of that in Net Income is a business with hidden strength.
• The Oncology Pivot: Moving into specialty pharmaceuticals and oncology (SCRI) is a smart move. It shifts the business from pure commodity logistics (low margin) to specialized care (higher margin).
• Price for Entry: This is a "steady Eddie" business. It doesn't need to double; it just needs to not break. It becomes attractive when the market forgets that boring is beautiful and prices it like a failing retailer rather than a systemic utility.

🐻 The Bear Case (Charlie inverts)

"Show me where I'll die and I won't go there."

• The Margin Razor: A net margin of 0.9% is a precarious place to live. A slight increase in labor costs, a fuel spike, or a minor regulatory shift doesn't just trim profits—it deletes them. One bad quarter of operational inefficiency and the business is underwater.
• The Direct-to-Consumer Bypass: The permanent threat is disintermediation. If drug manufacturers (like Eli Lilly or Pfizer) decide the "middleman tax" is too high and build their own direct-to-provider logistics, McKesson’s massive network becomes a collection of expensive, empty warehouses.
• The Regulatory Guillotine: The U.S. government is perpetually eyeing drug pricing. While MCK is a distributor, any legislation that caps the "spread" or mandates fixed margins for wholesalers would permanently cap the upside and destroy the ability to pass on costs.
• Most Likely Threat: Disintermediation via "Platform" players (Amazon/Direct-Manufacturer). Timeframe: 5–10 years.

💰 Valuation & Margin of Safety

The DCF is a helpful map, but the map is not the territory.

• Intrinsic value estimate: $516.48 per share.
• 25% margin of safety entry: $387.36 (Conservative: Protects against a margin squeeze).
• 50% margin of safety entry: $258.24 (Buffett's ideal: The "fat pitch" price).
• Current Status: Expensive. With the market price trading above the $516.48 intrinsic value, we are paying for growth that the business's own anemic margins cannot realistically support. We are buying at a premium for a company that operates on a razor's edge.

Verdict: WATCH

Price currently exceeds intrinsic value, providing zero margin of safety. The moat is wide but the margins are dangerously thin. We wait for a market panic to bring the price toward $400.